DNLIHealthcare · BiotechnologyThe 20 Wall Street analysts covering Denali Therapeutics, Inc. hold a median 12-month price target of $35 — +40.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Denali Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (84): The shares have been drifting up relative to others.
Growth (37): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (28): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DNLI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +40.4% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | UBS | Maintains | Buy | $25 → $34 |
| 23 July 2026 | Morgan Stanley | Maintains | Overweight | $35 → $36 |
| 23 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 16 July 2026 | Deutsche Bank | Maintains | Buy | $31 → $35 |
| 16 July 2026 | Deutsche Bank | Maintains | Buy | — |
| 13 July 2026 | JP Morgan | Reinstates | Overweight | $29 |
| 26 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 11 May 2026 | BTIG | Reiterates | Buy | — |
| 8 May 2026 | Wedbush | Maintains | Outperform | — |
| 22 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 7 Apr 2026 | Baird | Maintains | Outperform | — |
| 26 Mar 2026 | Baird | Maintains | Outperform | — |
| 26 Mar 2026 | Goldman Sachs | Maintains | Buy | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
| 26 Mar 2026 | Stifel | Maintains | Buy | — |
| 25 Mar 2026 | BTIG | Maintains | Buy | — |
| 2 Mar 2026 | BTIG | Maintains | Buy | — |
| 24 Feb 2026 | Wolfe Research | Initiates | Peer Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DNLI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 1% of US stocks
Cheaper than 23% of US stocks
Cheaper than 80% of US stocks
Higher than 99% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Denali Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Denali Therapeutics' stock rose 33.1% over three months, driven by strong uptake of its Avlayah launch. However, regulatory and pipeline risks remain for the company.
Why it matters — A DNLI watcher would care because the stock's recent gain is tied to the Avlayah launch, while ongoing regulatory and pipeline risks could affect the company's outlook.
AVLAYAH's approval has validated Denali Therapeutics' TransportVehicle platform, and the company is entering its commercial stage with early payer coverage and Q3 guidance supporting a credible launch ramp. The US label limits near-term potential, but zafinofusp alfa and four TV-enabled 2027 readouts offer pipeline upside.
Why it matters — A DNLI watcher would care because AVLAYAH's validation and upcoming 2027 pipeline readouts signal meaningful growth catalysts beyond the current label's limits.
Denali Therapeutics is shifting from a neuroscience platform to a commercial biotech with its FDA-approved rare-disease therapy AVLAYAH. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress.
Why it matters — This marks a key transition for DNLI as its AVLAYAH commercial launch and platform pipeline could shape its growth trajectory beyond the platform stage.
Denali Therapeutics narrowed its second-quarter loss, with Avlayah sales exceeding estimates and showing strong launch traction. The company also provided pipeline updates that are shaping its outlook.
Why it matters — A DNLI watcher would care because the narrowing loss and strong Avlayah launch momentum signal positive early commercial traction for the company's lead product.
Denali Therapeutics published the transcript of its Q2 2026 earnings call, as reported by Seeking Alpha. The item provides access to the company's quarterly discussion with analysts.
Why it matters — A DNLI watcher would care because the earnings call transcript offers insight into the company's most recent quarterly business update and management commentary.
The 20 Wall Street analysts covering Denali Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $27 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 analysts covering Denali Therapeutics, Inc., 19 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Denali Therapeutics, Inc. 64 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Denali Therapeutics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).
No one can know that. What the data says: the median 12-month target from 20 analysts implies +40.4% from the last close, and Ticker Nerd's factor model ranks Denali Therapeutics, Inc. 64 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Denali Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNLI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $42 over the next 12 months.
Denali Therapeutics, Inc. returned +63.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to address neurodegenerative and lysosomal storage diseases.
The most recent item we track (Zacks Investment Research, 20 Aug 2026): "DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?". Denali Therapeutics' stock rose 33.1% over three months, driven by strong uptake of its Avlayah launch. However, regulatory and pipeline risks remain for the company.
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to address neurodegenerative and lysosomal storage diseases. The company engineers product candidates using proprietary technologies such as Antibody Transport Vehicle (ATV) and Enzyme Transport Vehicle (ETV) to enable effective delivery across the blood-brain barrier, targeting challenging central nervous system disorders. Its pipeline includes programs like DNL310 (Tividenofusp alfa) for Hunter syndrome (MPS II), DNL126 for MPS IIIA (Sanfilippo Syndrome A), DNL343 (eIF2B activator) for amyotrophic lateral sclerosis, BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson's disease, Eclitasertib (DNL758, RIPK1 inhibitor) for peripheral inflammatory diseases, and others such as TAK-594/DNL593 for frontotemporal dementia-granulin and initiatives targeting TREM2 and Tau. Denali Therapeutics Inc. advances these candidates through clinical development, emphasizing innovative solutions for unmet needs in neurology and rare genetic disorders. Founded in 2013 and headquartered in South San Francisco, California, it plays a key role in the biotechnology sector dedicated to neurodegeneration.
CEO Dr. Ryan J. Watts Ph.D. · 503 employees · United States · https://www.denalitherapeutics.com